Review authors suggested guidelines to help in standardizing future lupus nephritis studies. Heterogeneity in lupus nephritis (LN) trial design substantially hinders interpretation of studied drugs’ ...

Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with expedited clinical development timelines Current Regenerative Medicine Advanced ...

Until biomarkers that can predict treatment response emerge, early and aggressive treatment is recommended in lupus nephritis ...

Yale researchers have identified CD8+ T cells as a key driver of kidney damage in lupus, challenging the long-standing focus on B cells. The discovery may explain why some patients do not respond to ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced its ...

Autolus Therapeutics plc (NASDAQ:AUTL) is also pioneering the use of CAR T-cells in autoimmune diseases; the LUMINA trial is ...

Kidney damage is a serious complication affecting individuals with lupus, an autoimmune disease where immune B cells ...

T-cell profiles derived from blood and renal biopsy may be novel biomarkers of lupus nephritis treatment response, study findings suggest.

The body's immune reaction to increased levels of a toxic molecule, part of a bacterial species in the human gut, may reveal ...

Short-term observational data support belimumab as a safe therapeutic option in patients with lupus nephritis, who are at increased risk of cancer. Over the short term, overall cancer risk may be ...

Patients who received obinutuzumab were less likely to experience a renal-related event or death, compared with those who received placebo. The Food and Drug Administration (FDA) has approved Gazyva ® ...

Gazyva (obinutuzumab) is a lab-made antibody medication used for treating certain blood cancers. The FDA recently approved the combined use of Gazyva and standard therapy in adults having an active ...